drugset / Trial / NCT01439789

Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients

NCT01439789 ↗

Phase 3 Terminated 146 enrolled Zensun Sci. & Tech. Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Multi-center, randomized, double-blind , placebo parallel controlled, standard therapy based phase III clinical trial, to evaluate the efficacy of recombinant human neuregulin-1 on serum NT-proBNP, as well as safety in patients with chronic heart failure.

Timeline

Start
2011-06
Primary completion
2012-06
Completion
2012-06

Outcome

Outcome not reported

Stopped: “Sponsor has designed another study with different endpoint to replace the current study”

Drugs

EvaluationDrugModalityDoseRoute
Comparator HUMAN NEUREGULIN-1 RECOMBINANT (177-237) Protein / enzyme biologic 0.6 ug/kg Intravenous

Indications